Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) EBT (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed EBT for 15 consecutive years, with -$10.6 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 2870.68% to -$10.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$24.2 million, a 21741.44% decrease, with the full-year FY2025 number at -$13.7 million, down 32.44% from a year prior.
  • EBT was -$10.6 million for Q4 2025 at Aytu Biopharma, down from $2.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $3.8 million in Q1 2025 to a low of -$53.1 million in Q1 2022.
  • A 5-year average of -$9.2 million and a median of -$6.7 million in 2022 define the central range for EBT.
  • Biggest YoY gain for EBT was 316.07% in 2025; the steepest drop was 8579.91% in 2025.
  • Aytu Biopharma's EBT stood at -$11.6 million in 2021, then soared by 42.06% to -$6.7 million in 2022, then soared by 120.9% to $1.4 million in 2023, then tumbled by 72.69% to $382000.0 in 2024, then tumbled by 2870.68% to -$10.6 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's EBT are -$10.6 million (Q4 2025), $2.0 million (Q3 2025), and -$19.4 million (Q2 2025).